Cell Biotech Co (XKRX:049960) Cash-to-Debt : 45.22 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Cell Biotech Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cell Biotech Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 45.22.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cell Biotech Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Cell Biotech Co's Cash-to-Debt or its related term are showing as below:

XKRX:049960' s Cash-to-Debt Range Over the Past 10 Years
Min: 40.81 Med: 5034.99 Max: No Debt
Current: 45.22

During the past 13 years, Cell Biotech Co's highest Cash to Debt Ratio was No Debt. The lowest was 40.81. And the median was 5034.99.

XKRX:049960's Cash-to-Debt is ranked better than
71.69% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs XKRX:049960: 45.22

Cell Biotech Co Cash-to-Debt Historical Data

The historical data trend for Cell Biotech Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cell Biotech Co Cash-to-Debt Chart

Cell Biotech Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

64.02

40.81

69.99

68.19

45.22

Cell Biotech Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															68.19	69.73	74.03	39.58	45.22

Competitive Comparison of Cell Biotech Co's Cash-to-Debt

For the Biotechnology subindustry, Cell Biotech Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Biotech Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Biotech Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cell Biotech Co's Cash-to-Debt falls into.

Cell Biotech Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cell Biotech Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	70332.176	/	(621.143	+	934.167)
	=	45.22

Cell Biotech Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	70332.176	/	(621.143	+	934.167)
	=	45.22

Cell Biotech Co (XKRX:049960) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cell Biotech Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cell Biotech Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cell Biotech Co (XKRX:049960) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Biotech Co Ltd (XKRX:049960) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

134 Gaegok-ri, Wolgot-myeon, Gimpo-si, Gyeonggi-Do, KOR, 415-872

Website

http://www.cellbiotech.com

Cell Biotech Co Ltd is a specialized biotech company. It is engaged in the fermentation and coating technology development as well as manufacturing probiotics and lactic acid bacteria. The key product consists Probiotic DUOLAC, Nutra DUOLAC, LACTOClear, and LAB2PRO. The company distributes its products within domestic market and to overseas markets.

Cell Biotech Co (XKRX:049960) Headlines

No Headlines